Basf Aktiengesellschaft

Knoll Aktiengesellschaft

Reinhard Spengler

Dieter Horn

Axel Sanner

Hartmut Hibst

Klaus Harth

Roger G Klimesch

Siegfried Lang

Sven Grabowski

Hans-Helmut Goertz

Miguel Fernandez Brana

Jose Maria Berlanga

Christine Tetzner

Ernst Flaig

Winfried Mueller

Goetz Krueger

Klaus Laemmerhirt

Juergen Dembowski

A novel delayed-release form for pharmaceutical active compounds, characterized by a core containing the active compound and a diffusion-inhibiting, adhesive coating layer having a thickness in the range from 0.01 to 10 .mu.m, consisting of a chemical network which has been applied to the support in a plasma-assisted chemical deposition process, and a process for its production are described.

Delayed-release form for pharmaceutical active compounds

A solid depot drug form produced by melt extrusion at from 50.degree. to 200.degree. C. and continuous shaping of a mixture of from 0.1 to 70% by weight, based on the finished depot form, of a pharmaceutical active ingredient with a polymer melt of the following composition:

Solid depot drug form

The monohydrochloride and the monomethanesulfonate of amonafide are described. The salts have good pharmaceutical properties besides their antitumor action.

Amonafide salts

An aqueous or pulverulent, water-dispersible pharmaceutical preparation which contains an emulsifier, a protective colloid and, in microdisperse form, an edible oil or fat, a sparingly water-soluble active compound being dissolved in the oil or fat, and a process for its preparation.

Aqueous or pulverulent, water-dispersible preparation of a sparingly

A hydrophilic theophylline powder formulation consisting of

Hydrophilic theophylline powder formulation and its preparation

Pulverulent, water-dispersible preparation of a sparingly water-soluble

Process for the preparation of solid pharmaceutical forms by mixing one or more pharmaceutical active compounds with one or more fusible, pharmacologically tolerated binders and, if required, other conventional pharmaceutical auxiliaries, at from 50.degree. to 180.degree. C., and subjecting the mixture to injection molding or extrusion and shaping, wherein the fusible binder used is a NVP polymer which contains not less than 20% by weight of NVP as copolymerized units, and, where they are present, all of whose comonomers contain nitrogen and/or oxygen.

Preparation of solid pharmaceutical forms

Growing community of inventors

Ludwigshafen, Germany

Reinhard Spengler